Table 1.

Comparison of Patient and Xenografts Chemosensitivity Profiles

Identification Number	Diagnosis	Tumor Type	IDH Status	Treatment	Patient Clinical Response	PDX Inhibitory Response
GBM18-33	Glioblastoma, IDH-wild type, CNS WHO grade 4	Recurrent	Wild Type	Carboplatin	PD	−
GBM18-35-1	Glioblastoma, IDH-wild type, CNS WHO grade 4	Primary	Wild Type	Temozolomide	PD	−
GBM18-35-2	Glioblastoma, IDH-wild type, CNS WHO grade 4	Recurrent	Wild Type	Carboplatin	PD	−
GBM18-38	Glioblastoma, IDH-wild type, CNS WHO grade 4	Recurrent	Wild Type	Carboplatin	PD	−
GBM18-39	Glioblastoma, IDH-wild type, CNS WHO grade 4	Recurrent	Wild Type	Carboplatin	PD	−
GBM19-42	Glioblastoma, IDH-wild type, CNS WHO grade 4	Primary	Wild Type	Temozolomide	PR	+
ASTRO19-43	Astrocytoma, IDH-mutant, CNS WHO grade 4	Recurrent	Mutated	Carboplatin	PD	−
OLIG19-45	Oligodentroglioma, IDH-mutant, CNS WHO grade 3	Recurrent	Mutated	Carboplatin	PD	−
ASTRO19-47	Astrocytoma, IDH-mutant, CNS WHO grade 4	Recurrent	Mutated	Temozolomide	SD	+
ASTRO19-48	Astrocytoma, IDH-mutant, CNS WHO grade 3	Recurrent	Mutated	Carboplatin	?	−
OLIG19-50	Oligodendroglioma, IDH-mutant, 1p/19q codeleted, CNS WHO grade 3	Primary	Mutated	Temozolomide	CR	+
GBM20-60	Glioblastoma, IDH-wild type, CNS WHO grade 4	Primary	Wild Type	Temozolomide	PD	−
ASTRO20-63	Astrocytoma, IDH-mutant, CNS WHO grade 4	Recurrent	Mutated	Carboplatin	SD	+
GBM20-66	Glioblastoma, IDH-wild type, CNS WHO grade 4	Recurrent	Wild Type	Carboplatin	PD	−
GBM20-68	Glioblastoma, IDH-wild type, CNS WHO grade 4	Primary	Wild Type	Temozolomide	CR	+

Abbreviations: GBM, glioblastoma; ASTRO, astrocytoma; OLIG, oligodendroglioma; PD, progressive disease; SD, stable disease; PR, partial ­response; CR, complete response.